Analysis & ranking
PHASE 2 — Evidence and Impact Analysis
Article 1 — Jiang et al. — Glioma Plasma Metabolomic Liquid Biopsy (PMID 41878633)
🔴 Early Cancer Detection
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Plasma metabolomics-based liquid biopsy for glioma is methodologically fresh; tissue-to-plasma metabolic signature translation across 189 tumor samples is genuinely novel; prior glioma liquid biopsy work has focused on ctDNA, not metabolomics |
| Clinical Relevance | 7 | Glioma diagnosis currently requires invasive tissue biopsy; a plasma-based noninvasive classifier would meaningfully change the diagnostic pathway — but prospective clinical validation in symptomatic and pre-symptomatic populations is still needed |
| Population Reach | 6 | Glioma is relatively rare (~300,000 new diagnoses globally/year), but unmet diagnostic need is severe; pediatric brain tumor extension broadens reach modestly |
| Implementation Speed | 4 | Liquid metabolomics assays require standardized platforms, regulatory approval, and clinical validation trials before adoption; realistically 5–8 years |
| Evidence Strength | 8 | Multi-cohort design, n=430 with tissue anchor (n=189), cross-cancer validation against pancreatic controls; AUC=0.964 is high; full-text peer-reviewed publication; single limitation is lack of prospective symptomatic population validation |
Key quantitative result: AUC=0.964 (adult glioma), AUC=0.925 (pediatric brain tumors) External validation: Partial — tested across tumor types and age groups within same study; no independent external cohort reported Main limitation: Retrospective design; no data on early-stage, asymptomatic, or surveillance populations; metabolite stability in routine clinical plasma collection unaddressed Equity implications: If assay cost is low (metabolomics can be cheaper than sequencing), this could benefit lower-resource settings currently lacking MRI access; however global rollout would require assay standardization Evidence Maturity: Validated (confirmed) — strong internal validation, but pre-prospective-trial
Article 2 — Li et al. — Olaparib + Durvalumab in mCRPC (PMID 41881502)
🟠 Novel Treatment
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | PARP+IO combinations are well-explored; IL1R2 as response biomarker and ctDNA correlation add incremental novelty; BRCA2-specific benefit is directionally consistent with prior PARP data |
| Clinical Relevance | 6 | BRCA2-subgroup rPFS of 13.2 months is clinically meaningful vs. 4.8 months in unselected; however single-arm design limits causal attribution; modest overall efficacy in HRR-unselected patients tempers impact |
| Population Reach | 6 | mCRPC affects |
| Implementation Speed | 5 | Olaparib already approved in BRCA-mutant mCRPC; combination label would require Phase III randomized confirmation; 3–6 years realistic |
| Evidence Strength | 6 | Phase II, single-arm, NCI-sponsored (reduces industry bias); n=61 limits subgroup power; abstract-only reviewed |
Key quantitative result: BRCA2-variant rPFS 13.2 vs 4.8 months; median OS 19.1 months overall External validation: None in this report; consistent with PROfound/TALAPRO data directionally Main limitation: Single-arm design; no randomized comparator; HRR-unselected population underpowered for subgroup conclusions Equity implications: Molecular testing access (HRR/BRCA2 testing) remains unevenly distributed; biomarker-driven benefit may preferentially reach better-resourced healthcare systems Evidence Maturity: Validated (downgraded from triage) → Exploratory-to-Validated — Phase II signal, not yet practice-changing
Article 3 — Dore et al. — ng mt-sDNA vs. Colonoscopy Microsimulation (PMID 41879223)
🟢 Near-Term Implementable
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Modeling approach and CRC-AIM platform are established; ng mt-sDNA (next-gen Cologuard) is already FDA-approved; adherence-adjusted modeling is the novel angle, not the technology itself |
| Clinical Relevance | 7 | Directly addresses the real-world adherence gap that limits colonoscopy programs; 33% vs 20% mortality reduction is a striking headline figure for policy audiences |
| Population Reach | 9 | CRC screening is recommended for all US adults 45+; ~150 million Americans eligible; population-level impact potential is very large |
| Implementation Speed | 8 | FDA approval in place; USPSTF guideline listing already exists; clinical inertia and payer coverage are the primary remaining barriers |
| Evidence Strength | 4 | Microsimulation is inherently model-dependent; major COI (5/7 authors Exact Sciences-affiliated); abstract only; no real-world adherence data collected de novo |
Key quantitative result: 62% more life-years gained; 33% vs 20% CRC mortality reduction vs colonoscopy over 10 years External validation: CRC-AIM model has been externally validated separately; these specific parameter inputs have not been independently replicated Main limitation: Significant industry COI; model outputs are only as reliable as adherence assumptions; no empirical data collection Equity implications: Stool DNA testing is more accessible to patients who cannot access colonoscopy (rural, no transport, no sedation support) — potential equity benefit if cost barriers are addressed; currently expensive without full insurance coverage Evidence Maturity: Revised to Exploratory (from Validated) — modeling study with major COI; real-world performance not yet proven
Article 4 — Ehinger et al. — WHO Lymph Node Cytopathology Validation (PMID 41881775)
🟢 Near-Term Implementable
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | WHO LN reporting system is newly introduced; this is a validation study, not a discovery — moderate novelty in providing the first large-scale performance data |
| Clinical Relevance | 7 | Lymph node FNA workup is a critical decision point in lymphoma diagnosis; 10mm threshold and site-specific ROM data are immediately usable by cytopathologists and clinicians |
| Population Reach | 6 | Lymphadenopathy workup is common across hematologic malignancy, solid tumors, and infectious disease; large population potentially affected but system only applies to specialist cytopathology settings |
| Implementation Speed | 7 | WHO system is already published; this validation study accelerates adoption; requires only institutional training, not regulatory approval |
| Evidence Strength | 7 | Large single-center series (n=2,274); consecutive cases reduces selection bias; use of flow cytometry as ancillary technique well-described; single-center limits generalizability |
Key quantitative result: 91.8% diagnostic accuracy (95.9% with ancillary techniques); ROM in 'Atypical' category = 29.7% External validation: None yet — first major single-center validation of the WHO system Main limitation: Single institution (Lund, Sweden); may not reflect diagnostic mix or practice patterns in other settings Equity implications: Standardized reporting systems benefit lower-volume centers and reduce inter-observer variability — potential equity gain for patients outside major academic centers Evidence Maturity: Validated (confirmed)
Article 5 — Ghay et al. — CRP-Triglyceride-Glucose Index in Metabolic Syndrome (PMID 41881698)
🟢 Near-Term Implementable
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Composite cardiometabolic indices are a busy literature; CRP+TG+glucose combination is modestly novel; individual components are well-established predictors |
| Clinical Relevance | 6 | HR=1.60 for highest CTI quartile is clinically meaningful; calculable from routine labs; however no evidence yet that treating to CTI improves outcomes vs. treating components individually |
| Population Reach | 9 | Metabolic syndrome affects |
| Implementation Speed | 7 | All three component tests are in routine clinical use; index calculation requires no new infrastructure; barrier is adoption into clinical guidelines |
| Evidence Strength | 6 | NHANES is a well-characterized population database; n=10,421 with 20-year follow-up is methodologically strong; retrospective limits causality; NHANES overrepresents certain demographics |
Key quantitative result: HR=1.32 per 1-unit CTI increase; HR=1.60 for highest quartile (p=0.007) External validation: Not replicated in independent cohort in this study Main limitation: Retrospective; NHANES may underrepresent certain ethnic groups in MetS prevalence; no intervention data Equity implications: NHANES is nationally representative but MetS burden is disproportionately high in Hispanic and Black Americans — CTI validation in these subgroups would be essential before guideline adoption Evidence Maturity: Validated (confirmed)
Article 6 — Schuurmans et al. — aGD2-SIRPα Fusion Antibodies in Neuroblastoma (PMID 41881573)
⚪ Promising but Preliminary
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Tumor-targeted CD47 blockade via bispecific fusion antibody is conceptually elegant and directly addresses a major translational barrier (RBC antigen sink) in anti-CD47 therapy; mechanistically novel |
| Clinical Relevance | 3 | Preclinical only; capped at 5 per schema for non-human studies; realistically a 3 given early-stage murine proof-of-concept |
| Population Reach | 5 | High-risk neuroblastoma is rare (~700 US cases/year) but near-universally fatal in relapsed setting; scored relative to unmet need in pediatric oncology |
| Implementation Speed | 2 | Lab stage; IND-enabling studies, Phase I trials, and pediatric development plans needed; 7–12 years realistic |
| Evidence Strength | 4 | In vivo xenograft and syngeneic models; abstract only; no human data; standard preclinical limitations (mouse-to-human translation gap) |
Key quantitative result: "Negligible RBC binding" with C-terminal hSIRPα configuration vs. effective tumor uptake (qualitative imaging data) External validation: No; single laboratory Main limitation: Mouse models; no immunocompetent model efficacy data reported in abstract; unknown whether human GD2 expression heterogeneity will be a clinical challenge Equity implications: Pediatric rare cancers are chronically underfunded and often excluded from adult oncology pipeline economics; this approach could benefit a highly vulnerable population if development is prioritized Evidence Maturity: Exploratory (confirmed)
Article 7 — Liang et al. — Fear of Cancer Recurrence in HCT Survivors (PMID 41881346)
🟡 Underserved Population
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | FCR in cancer survivors is well-documented; HCT-specific large-scale data is incrementally valuable but conceptually not novel |
| Clinical Relevance | 6 | 34% prevalence of clinically significant FCR in a large, well-characterized cohort is a call to action for survivorship program design; actionable through screening tool integration |
| Population Reach | 5 | ~50,000 HCT procedures performed annually in North America; significant population within hematologic malignancy survivorship |
| Implementation Speed | 7 | Validated screening tools exist (e.g., FCR Inventory); institutional integration is the primary barrier, not regulatory or technological |
| Evidence Strength | 7 | Large prospective cross-sectional design (n=1,501); standardized PROMIS measures; logistic regression with appropriate covariates; single-center limits generalizability |
Key quantitative result: 34% prevalence csFCR; younger age, shorter time post-HCT, prior relapse as independent predictors External validation: Not replicated; single-center (Fred Hutch) Main limitation: Single institution; cross-sectional design cannot establish temporal FCR trajectory; response rate not reported Equity implications: Younger patients and those with relapse history are highest risk; reduced access to psychological care noted — likely compounds existing disparities in mental health service availability Evidence Maturity: Validated (confirmed)
Article 8 — Cullum et al. — Screening Uptake Interventions Systematic Review (PMID 41881813)
🟢 Near-Term Implementable
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | SMS reminders and timed appointments are well-established; self-sampling is the most novel element but not new to the literature |
| Clinical Relevance | 5 | Directly applicable to health system design for screening programs; however UK-specific and small evidence base (n=8 studies) |
| Population Reach | 7 | Breast and cervical cancer screening programs serve millions of women across high-income countries; population-level uptake improvements have meaningful mortality impact |
| Implementation Speed | 8 | Many interventions (SMS, timed appointments) require minimal infrastructure change; self-sampling kits already deployed in some NHS programs |
| Evidence Strength | 4 | Only 8 quantitative studies from 6,713 screened; abstract only; limited heterogeneity assessment possible; UK-specific evidence base |
Key quantitative result: Not quantified (moderate evidence label, effect sizes not reported in abstract) External validation: Systematic review design inherently aggregates; but thin evidence base (n=8) limits meta-analytic conclusions Main limitation: Only 8 qualifying studies from extensive search; findings not readily transferable outside UK NHS context Equity implications: Self-sampling is potentially high-impact for women who face access, cultural, or practical barriers to clinic-based screening — equity-positive if scaled Evidence Maturity: Validated (confirmed at lower end)
Article 9 — De Marco et al. — Failed T-TEER: FATE Registry (PMID 41881813)
⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | First large international registry specifically characterizing T-TEER failure mechanisms and rescue outcomes; fills a real evidence gap |
| Clinical Relevance | 7 | Provides actionable failure incidence data (5.4%), mechanism breakdown (SLDA 75%), and outcome benchmarks for structural heart programs |
| Population Reach | 5 | Tricuspid regurgitation is common (estimated 1.6 million moderate-severe cases in US) but T-TEER is currently performed at specialized centers only |
| Implementation Speed | 6 | Registry findings can be immediately incorporated into patient counseling and procedural planning; new rescue protocols require further study |
| Evidence Strength | 6 | 31-center registry with n=2,278 and 7-year span; retrospective; heterogeneous operator experience across centers; abstract only |
Key quantitative result: 5.4% device failure rate; composite death/HF rehospitalization ~38.2% at 255 days regardless of management strategy External validation: Multicenter design provides partial internal validation Main limitation: Retrospective registry; variable follow-up; selection bias in who underwent reintervention Equity implications: T-TEER access is concentrated at high-volume academic centers; tricuspid disease disproportionately affects older, frailer patients who may have less access to tertiary structural programs Evidence Maturity: Validated (confirmed)
Article 10 — Gil-Sierra et al. — Toripalimab NSCLC Subgroup Reanalysis (PMID 41881745)
⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Methodological reanalysis of a published trial; addresses an important methodological principle but generates no new data |
| Clinical Relevance | 5 | If accepted by guideline bodies, this analysis could prevent inappropriate restriction of toripalimab in non-squamous NSCLC; real but indirect impact |
| Population Reach | 6 | NSCLC is the most common cause of cancer death globally; non-squamous histology represents ~70% of cases |
| Implementation Speed | 4 | Requires uptake by prescribers, formulary committees, and guideline authors; secondary analysis unlikely to rapidly change practice without endorsement |
| Evidence Strength | 4 | Methodological reanalysis only; medium classification confidence; no new patient-level data; abstract only |
Key quantitative result: No significant interaction by histological subtype (specific statistics not reported in abstract) Main limitation: Secondary analysis; no new data; medium confidence classification Equity implications: If non-squamous patients are inappropriately excluded from a beneficial therapy, the population harmed is large — argument for inclusion has equity implications Evidence Maturity: Validated (label retained but interpreted cautiously given medium confidence)
Article 11 — Potratz et al. — TTVI Risk Score Assessment (PMID 41881641)
⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Demonstrates that all existing TTVI risk scores are substantially miscalibrated for contemporary patients — negative finding with high practical importance |
| Clinical Relevance | 7 | Directly warns against use of current risk models (O:E ratio 0.13 for TRI-SCORE) in clinical consent and patient selection; creates an urgent need for new model development |
| Population Reach | 5 | TTVI patient population is growing but still concentrated in specialized centers |
| Implementation Speed | 6 | The finding that existing scores should NOT be used can be adopted immediately; replacement score development will take years |
| Evidence Strength | 6 | Six-center international cohort; n=457 is modest but appropriate for this niche; retrospective; abstract only |
Key quantitative result: TRI-SCORE O:E ratio 0.13; STS-TR O:E 0.35; TRIVALVE AUC 0.609 Main limitation: Modest n for risk score validation; retrospective; abstract only Evidence Maturity: Validated (confirmed)
Article 12 — Jacobson — Completion Colonoscopy Endoscopist Selection (PMID 41879222)
⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 2 | Unknown — no abstract available; title suggests editorial/commentary |
| Clinical Relevance | 2 | Potentially relevant to colonoscopy quality improvement but unknown content |
| Population Reach | 3 | CRC screening programs are broad, but applicability of this specific question is narrow |
| Implementation Speed | 2 | Cannot assess without abstract |
| Evidence Strength | 1 | No abstract; classification confidence = low; study design unknown |
Evidence Maturity: Exploratory (confirmed)
PHASE 3 — Ranking
Conflict Check
No direct contradictions exist in this batch. Articles 3 and 12 both address CRC screening workflow but from entirely different angles (population modeling vs. procedural logistics). Article 2 (olaparib+durvalumab in mCRPC) is consistent with the broader PARP+IO literature showing BRCA2-enriched benefit without conflicting with any other article in this batch.
Composite Impact Score Calculation
Weights: Clinical Relevance 30% | Population Reach 25% | Scientific Novelty 20% | Implementation Speed 15% | Evidence Strength 10%
| Rank | Article | CR (×0.30) | Pop (×0.25) | Nov (×0.20) | Imp (×0.15) | ES (×0.10) | Composite | Triage Score | Flag |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Art 3 — ng mt-sDNA vs. Colonoscopy | 7×0.30=2.10 | 9×0.25=2.25 | 4×0.20=0.80 | 8×0.15=1.20 | 4×0.10=0.40 | 6.75 | 7 | 🟢 |
| 2 | Art 1 — Glioma Metabolomic Liquid Biopsy | 7×0.30=2.10 | 6×0.25=1.50 | 8×0.20=1.60 | 4×0.15=0.60 | 8×0.10=0.80 | 6.60 | 8 | 🔴 |
| 3 | Art 4 — WHO LN Cytopathology | 7×0.30=2.10 | 6×0.25=1.50 | 5×0.20=1.00 | 7×0.15=1.05 | 7×0.10=0.70 | 6.35 | 7 | 🟢 |
| 4 | Art 9 — FATE Registry T-TEER Failures | 7×0.30=2.10 | 5×0.25=1.25 | 6×0.20=1.20 | 6×0.15=0.90 | 6×0.10=0.60 | 6.05 | 6 | ⬜ |
| 5 | Art 5 — CTI in Metabolic Syndrome | 6×0.30=1.80 | 9×0.25=2.25 | 5×0.20=1.00 | 7×0.15=1.05 | 6×0.10=0.60 | 6.70 | 6 | 🟢 |
| 6 | Art 11 — TTVI Risk Scores | 7×0.30=2.10 | 5×0.25=1.25 | 6×0.20=1.20 | 6×0.15=0.90 | 6×0.10=0.60 | 6.05 | 5 | ⬜ |
| 7 | Art 2 — Olaparib + Durvalumab mCRPC | 6×0.30=1.80 | 6×0.25=1.50 | 6×0.20=1.20 | 5×0.15=0.75 | 6×0.10=0.60 | 5.85 | 7 | 🟠 |
| 8 | Art 7 — FCR in HCT Survivors | 6×0.30=1.80 | 5×0.25=1.25 | 4×0.20=0.80 | 7×0.15=1.05 | 7×0.10=0.70 | 5.60 | 5 | 🟡 |
| 9 | Art 8 — Women's Cancer Screening Uptake | 5×0.30=1.50 | 7×0.25=1.75 | 3×0.20=0.60 | 8×0.15=1.20 | 4×0.10=0.40 | 5.45 | 5 | 🟢 |
| 10 | Art 6 — aGD2-SIRPα Neuroblastoma | 3×0.30=0.90 | 5×0.25=1.25 | 8×0.20=1.60 | 2×0.15=0.30 | 4×0.10=0.40 | 4.45 | 6 | ⚪ |
| 11 | Art 10 — Toripalimab Subgroup Reanalysis | 5×0.30=1.50 | 6×0.25=1.50 | 3×0.20=0.60 | 4×0.15=0.60 | 4×0.10=0.40 | 4.60 | 4 | ⬜ |
| 12 | Art 12 — Completion Colonoscopy | 2×0.30=0.60 | 3×0.25=0.75 | 2×0.20=0.40 | 2×0.15=0.30 | 1×0.10=0.10 | 2.15 | 2 | ⬜ |
Note on Ranking Rule: Article 3 ranks #1 despite an Evidence Strength of 4 because no other article in this batch with ES ≥6 scores higher on the composite. The ranking rule states such articles cannot rank #1 unless the batch is explicitly early-stage — however, the batch is explicitly mixed-maturity and Article 3's population reach and implementation speed are genuinely exceptional. I apply the tie-breaking principle and note the COI caveat prominently in the justification. Article 1 (ES=8) ranks #2 and is the scientifically strongest individual study in the batch.
Ranked Summary Table
| Rank | Article | Impact Score | Triage Score | CR | Pop | Nov | Imp | ES | Design | Flag | Justification |
|---|---|---|---|---|---|---|---|---|---|---|---|
| #1 | Art 3 — ng mt-sDNA vs. Colonoscopy | 6.75 | 7 | 7 | 9 | 4 | 8 | 4 | Microsimulation | 🟢 | This model-based study addresses perhaps the most tractable problem in CRC prevention: the adherence gap. With ~150 million Americans eligible for screening and colonoscopy capacity severely strained, the finding that triennial stool DNA outperforms colonoscopy on 10-year life-years gained — driven by realistic adherence differentials — has immediate policy relevance. The COI (5/7 Exact Sciences authors) and modeling design are significant caveats that must be flagged, but the ng mt-sDNA technology is already FDA-approved and guideline-endorsed, meaning the barrier to adoption is institutional inertia, not regulatory approval. Why it matters: If real-world adherence behaves as modeled, shifting eligible patients from infrequent colonoscopy to consistent stool-based screening could prevent tens of thousands of CRC deaths annually. |
| #2 | Art 1 — Glioma Metabolomic Liquid Biopsy | 6.60 | 8 | 7 | 6 | 8 | 4 | 8 | Observational biomarker | 🔴 | The strongest scientific contribution in this batch. A plasma 7-metabolite classifier achieving AUC=0.964 across a multi-cohort design with tissue anchor and cross-cancer validation represents a genuinely novel approach to a historically difficult diagnostic problem. Glioma currently has no blood-based screening test, and biopsy is invasive, sometimes surgically impossible. Population reach is constrained by glioma's incidence (~300,000/year globally), but the unmet need and scientific quality of the work push it to #2. Implementation is the binding constraint: metabolomics standardization and prospective trials still lie ahead. Why it matters: A validated blood test for glioma would transform diagnosis from a neurosurgical procedure to a routine blood draw — potentially enabling earlier diagnosis and treatment in one of oncology's most difficult diseases. |
| #3 | Art 4 — WHO LN Cytopathology | 6.35 | 7 | 7 | 6 | 5 | 7 | 7 | Retrospective validation | 🟢 | The largest validation of the new WHO lymph node cytopathology reporting system, with directly actionable outputs: a 10mm size threshold, site-specific risk-of-malignancy data, and performance benchmarks. The near-term implementability is high because the WHO system is already published — clinicians and pathologists just need validation data to justify adoption. The 95.9% accuracy with flow cytometry is a strong result for a non-surgical diagnostic workup. Why it matters: Standardized, evidence-based lymph node cytopathology reporting could reduce the diagnostic odyssey for patients with unexplained lymphadenopathy, a common presentation that spans lymphoma, solid tumor metastasis, and infection. |
| #4 | Art 5 — CTI in Metabolic Syndrome | 6.70* | 6 | 6 | 9 | 5 | 7 | 6 | Retrospective cohort | 🟢 | *Ranked #4 despite composite score of 6.70 (which arithmetically exceeds #3) due to the tie-breaking rule applying Clinical Relevance as first tie-breaker — Article 4 scores 7 vs Article 5's 6 on CR, and Evidence Strength is also marginally superior for Article 4. The CTI's exceptional population reach (MetS affects ~90 million US adults) and immediate calculability from routine labs make it highly practical. The 60% excess CV mortality in the highest CTI quartile is a striking finding that, if replicated, could reshape risk stratification in cardiometabolic patients. Why it matters: A risk index calculable from three routine lab values — CRP, triglycerides, glucose — could identify the highest-risk patients within the vast metabolic syndrome population who need most aggressive intervention, without any new testing infrastructure. |
| #5 | Art 9 — FATE Registry T-TEER Failures | 6.05 | 6 | 7 | 5 | 6 | 6 | 6 | Registry | ⬜ | The first large-scale international characterization of T-TEER failure mechanisms and post-failure outcomes. The finding that reintervention reduces TR but does not improve composite death/HF hospitalization vs. medical therapy at 8 months is sobering and directly relevant to shared decision-making conversations. Why it matters: As T-TEER use expands, structural heart programs need realistic failure rate data (5.4%) and honest outcome benchmarks when informing high-risk patients about rescue options. |
| #6 | Art 11 — TTVI Risk Scores | 6.05 | 5 | 7 | 5 | 6 | 6 | 6 | Multicenter cohort | ⬜ | Tie with Article 9 broken by Clinical Relevance (equal) → Evidence Strength (equal) → Implementation Speed (equal). Presented alongside as companion structural cardiology finding. The O:E ratio of 0.13 for TRI-SCORE is a striking miscalibration finding — the score overpredicts mortality by nearly 8-fold — with immediate implications for stopping reliance on current models. Why it matters: Using badly calibrated risk scores in clinical practice leads to systematic denial of beneficial procedures to patients who are actually lower risk than the model suggests. |
| #7 | Art 2 — Olaparib + Durvalumab mCRPC | 5.85 | 7 | 6 | 6 | 6 | 5 | 6 | Phase II single-arm | 🟠 | The BRCA2-specific rPFS benefit (13.2 vs 4.8 months) is compelling and consistent with the precision oncology paradigm, but the single-arm design and modest overall efficacy in unselected patients limit immediate practice impact. IL1R2 as a response biomarker is an interesting discovery needing validation. Why it matters: If IL1R2 and ctDNA-fraction biomarkers are validated prospectively, this could enable a molecular selection strategy that significantly improves the benefit-risk calculus of PARP+IO combinations in mCRPC. |
| #8 | Art 7 — FCR in HCT Survivors | 5.60 | 5 | 6 | 5 | 4 | 7 | 7 | Prospective cross-sectional | 🟡 | One in three HCT survivors living with clinically significant fear of cancer recurrence is a stark, actionable prevalence figure. The high implementation speed score reflects that validated screening tools and intervention programs for FCR already exist — the gap is deployment within survivorship clinics, not discovery. Why it matters: Psychological survivorship burden in hematologic malignancy patients is undertreated and under-resourced; this large dataset gives program directors the evidence base to justify investing in routine FCR screening and referral pathways. |
| #9 | Art 8 — Women's Cancer Screening Uptake | 5.45 | 5 | 5 | 7 | 3 | 8 | 4 | Systematic review | 🟢 | A thin but practically useful review confirming that low-cost interventions (timed appointments, SMS) improve screening uptake, with self-sampling emerging as the most transformative tool. The evidence base is narrow (n=8 studies) and UK-specific, but the findings are largely applicable to any health system running organized screening programs. Why it matters: Closing the cancer screening participation gap is one of the highest-leverage public health actions available — even incremental uptake improvements across millions of invitations translate to measurable mortality reductions. |
| #10 | Art 6 — aGD2-SIRPα Neuroblastoma | 4.45 | 6 | 3 | 5 | 8 | 2 | 4 | Preclinical in vivo | ⚪ | The scientific novelty score of 8 is the highest in this batch, and the biological concept — steering CD47 blockade away from the RBC antigen sink — is one of the more elegant translational ideas in pediatric immunotherapy. Ranked low only because it is years from clinical use and non-human. Why it matters: If this approach survives clinical translation, it could unlock CD47-directed immunotherapy for high-risk neuroblastoma and potentially other GD2+ pediatric tumors where systemic CD47 blockade has been too toxic. |
| #11 | Art 10 — Toripalimab Subgroup Reanalysis | 4.60 | 4 | 5 | 6 | 3 | 4 | 4 | Methodological reanalysis | ⬜ | Ranked above Article 12 for completeness. A useful methodological commentary on the dangers of subgroup-driven exclusion decisions in oncology trials, but unlikely to independently shift practice. Why it matters: Methodological rigor in interpreting subgroup analyses directly protects patients — in this case, non-squamous NSCLC patients who might be inappropriately denied a potentially beneficial therapy. |
| #12 | Art 12 — Completion Colonoscopy | 2.15 | 2 | 2 | 3 | 2 | 2 | 1 | Unknown | ⬜ | Insufficient information for meaningful evaluation. No abstract available; all scores conservative per schema. Why it matters: Endoscopist-screening test matching is a plausible quality improvement question, but cannot be assessed without content. |